Introduction
The sulfonylurea receptor SUR1 (ABCC8) and potassium inward rectifier Kir6.2 (KCNJ11) genes encode subunits of the ATP-sensitive potassium (KATP) channel, which regulate insulin secretion by β-cells through coupling the metabolic state of the cell to membrane potential [1] . The KCNJ11 and ABCC8 genes are adjacent to each other on chromosome 11p15.1 [2] . The product of KCNJ11 forms the channel pore consisting of four Kir6.2 potassium inward rectifier subunits whereas four SUR1 subunits constitute an intracellular regulatory tetramer of the KATP channel [1] . The KATP channel contains 12 nucleotide-binding sites, of which eight reside on SUR1 and 4 on Kir6.2 [3] . The sites on Kir6.2 mediate the inhibitory effect of ATP whereas SUR1 is required for sensitivity to sulfonylureas and for activation by Mg-ADP. The activity of islet KATP channels is tightly regulated by plasma glucose levels whose increase leads to the closure of the channel pore and in turn stimulates insulin secretion [4] .
Replication of association between polymorphisms of the pancreatic ATP-sensitive potassium channel and susceptibility to type 2 diabetes in two Russian urban populations
The role of the E23K variant of KCNJ11 (marker rs5219) in impaired insulin secretion, β-cell dysfunction and type 2 diabetes (T2D) is well established. The allele K23 is associated with a higher diabetes risk showing an overall Odds Ratio (OR) of 1.23 in Caucasians [5, 6] . Carriers of the risk K23 allele showed altered β-cell function resulted in reduced glucose-stimulated insulin response since this allele is associated with an increased open probability of the β-cell KATP channel and reduced insulin secretion [5, 7, 8] .
In contrast, studies on association between polymorphic variants of ABCC8 (particularly for the non-synonymous G716V and synonymous T759T substitutions located in exon 16 and exon 18 of ABCC8, respectively) and T2D produced conflicting results. Some studies found association of these polymorphisms with altered insulin secretion and glucose intolerance [9, 10] whereas other reports failed to show correlation between the carriage of these ABCC8 variants and diabetes-related metabolic traits [11, 12] . Furthermore, a large-scale meta-analysis of the data for the G716V and T759T markers yielded negative results [13] . Compared to these markers, a silent G-to-A nucleotide substitution in codon 1273 (R1273R; rs1799859) located in exon 31 of ABCC8 was assessed less frequently but showed consistent association with T2D [11, 14, 15] and diabetesrelated traits [16, 17] in several populations.
Although T2D is a heterogeneous collection of metabolic syndromes, defects in β-cell function seem to play a major role in T2D etiology because the majority of genetic variants conferring susceptibility to this pathology are involved in control of β-cell development and function [18] . Therefore, it would be interesting to evaluate whether the ABCC8 R1273R A/G and KCNJ11 E23K markers predispose to T2D and/or are associated with diabetes-related phenotypes in Russian patients. We performed a pilot study in a small Russian population sample (127 T2D patients and 117 normoglycemic controls) and found that these genetic variants are associated with T2D and also contribute to glucose intolerance and alterations in insulin secretion [19] . In this report, we present data confirming a role of the sequence variations of the pancreatic KATP channel in T2D using a significantly extended population cohort from two Russian cities (Moscow and Tyumen).
Experimental Procedures

Patients
We studied two populations samples from geographically distinct regions of Russian Federation and consisted of a total 1185 unrelated Russian individuals (588 T2D patients and 597 controls). According to the patients' questionnaires, a total of 1027 (86.7% of 1185) subjects had grandparents of Russian ancestry, whereas the remaining 134 patients had three grandparents of Russian ancestry and one of either Ukrainian or Belarusian descent, i.e. nations that are very close to Russians. The first sample comprised a total of 794 (402 diabetic and 392 non-diabetic) subjects resided in Moscow. The Moscow population sample comprised 244 (127 diabetic and 117 non-diabetic) patients studied previously [19] and 550 newly recruited subjects. The subjects were recruited by the Moscow Endocrinology Research Center. The second cohort collected by the Tyumen State Medical Academy contained a total of 391 Russian residents of Tyumen (Western Siberia) 186 of whom were affected by T2D whereas the remaining 205 people represented non-diabetic controls. Of 588 T2D patients, 306 (52%) were treated with metformin and other biguanides, 200 (34%) with sulfonylureas, 147 (25%) with thiazolidinediones, 111 (19%) with meglitinides, 53 (9%) with glucagon-like peptide analogs and agonists, 49 (8%) with insulin and insulin analogs, 30 (5%) with α-glucosidase inhibitors, and 18 (3%) with dipeptidyl peptidase-4 inhibitors. 176 (30%) diabetic subjects underwent a mixed therapy with two or more anti-diabetic drugs.
All the control individuals were normoglycemic and had no clinical diabetes. T2D was defined according to the World Health Organization (WHO) diagnostic criteria as either a fasting plasma glucose concentration ≥7.8 mmol/l or a postprandial plasma glucose concentration ≥11.1 mmol/l 2 h after a 75-g oral glucose [20] and/or treatment by glucoselowering agents. Hypertension was defined as systolic pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg in at least two separate measurements or in case of a hypertension history. Obesity was defined as when body mass index (BMI) ≥30 kg/m 2 [21] . The controls had no past history of glucose intolerance, glycated hemoglobin (HbA1c) level of <6.4% or a normal oral glucose tolerance test (OGTT), and no family history of diabetes. To avoid interferences with biological variables, people with previous diagnosis of type 1 diabetes, gestational diabetes, rare forms of T2D, secondary diabetes (pancreatitis, chemochromatosis), and hypercholesterolaemia or those undergoing a treatment with cholesterol-lowering drugs were excluded from the study. The study protocol was approved by the Review Board of the Endocrinology Research Center, and all participants provided written informed consent. Clinical and metabolic characteristics of diabetic and non-diabetic patients are summarized in Table 1 . Replication of association between polymorphisms of the pancreatic ATP-sensitive potassium channel and susceptibility to type 2 diabetes in two Russian urban populations
Biochemical measurements
A standard 75-g OGTT was performed after a 12-h overnight fast according to the WHO recommendations [20] . HbA1c was measured using an ion-exchange high performance liquid chromatography (normal reference range: 4.1-6.4%). Blood serum glucose was measured using the Glucose Assay Kit (BioVision, Mountain View, CA, USA). Plasma insulin levels were determined by means of an enzymatic immunoassay (Insulin Assay Kit, CisBio Bioassays, Bedford, MA, USA). Homeostasis model assessment of β-cell function (HOMA-β) was calculated as 20 x fasting plasma insulin (mU/l)/ fasting glucose (mmol/l) -3.5 [22] . The change of each characteristics in a period of a 6-month treatment with a diabetic drug (Δ value) was calculated as: Δ value= (baseline (T 0 ) value -T 6-months value) x 100%.
DNA analysis
Total DNA was isolated from whole-blood samples pretreated with proteinase K using a standard protocol for extraction with phenol-chloroform (Fermentas, Vilnius, Lithuania). The marker rs5219 of KCNJ11 and rs1799859 of ABCC8 were studied using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach as previously described [19] . DNA digestion products were analyzed by electrophoresis in 8% polyacrylamide gel and visualized with silver nitrate staining [23] . Table 2 . Association of the KCNJ11 E23K variant with type 2 diabetes. To compare allele and genotype frequencies, the Yates' χ 2 test was used. Odds Ratios (ORs) were calculated to assess the strength of association. To assess the extent to which the various genotypes were associated with T2D, ORs and 95% confidence intervals (CI) were estimated by logistic-regression analysis. To provide separate ORs for each genotype, dummy variables were used with a wild-type genotype used as a reference group. In the multiple regression model age, sex, HbA1c, body mass index, obesity, and hypertension were included as covariates.
Statistical analysis
variables for the continuous traits were log-transformed before statistical comparisons were made. To compare quantitative data in groups of carriers of different genotypes, the unpaired Student's t-test was used. The test for Hardy-Weinberg equilibrium and comparison of genotype and allele frequencies in the T2D subjects and controls were performed using the χ 2 test. To assess the extent to which the various genotypes were associated with T2D, ORs and 95% confidence intervals (CI) were estimated by logistic-regression analysis. To provide separate ORs for each genotype, dummy variables were used, with a wild-type genotype used as a reference group. The significance of interaction between clinical characteristics and polymorphic variants was assessed using a two-way ANOVA. Observed relationships were then adjusted for patients' conventional risk factors by analysis of covariance (ANCOVA) using age, gender, HbA1c, BMI, obesity, and hypertension as covariates. P-values of less then 0.05 were considered significant. The attributable population risk (PAR) was computed using the empirical Levin's formula and its modification when confounding exists and when, as a result, adjusted ORs must be used [24] . To estimate the genetic power of the sample tested, the Genetic Power Calculator was used [25] . Table 3 . Association of the ABCC8 R1273R G/A variant with type 2 diabetes. The legend is the same as that for Table 2 .
Results
Association of the KCNJ11 E23K and ABCC8 R1273R G/A variants with T2D
For KCNJ11 E23K, power estimates showed that the total population sample has at least 99.9% power (α=0. Table 4 . Association of the E23K KCNJ11 variant with glucose tolerance and β-cell function. Results are given as mean ± S.D. The variables were compared using the two-way ANOVA test. Observed relationships were then adjusted for patients' conventional risk factors by the ANCOVA analysis using age, gender, HbA1c, body mass index, obesity and hypertension as covariates. Abbreviations: HbA1c, glycated hemoglobin; HOMA-β, homeostasis model assessment of β-cell function; S.D., standard deviation. Table 5 . Association of the ABCC8 R1273R G/A variant with glucose tolerance and β-cell function. The legend is the same as that for Table 4 .
genetic effects of both polymorphisms on susceptibility to T2D. The KCNJ11 E23K and ABCC8 G/A R1273R markers both obeyed the Hardy-Weinberg equilibrium (data not shown). In Moscow population, the carriage of the K23 allele and homozygous K/K genotype of KCNJ11 was associated with increased risk of T2D (OR=1.41, P=0.0014 and OR=2.35, P=0.0004, respectively). Similarly, the KCNJ11 K23 variant was shown to confer susceptibility to T2D in Tyumen patients (Table 2 ). In the pooled population sample, the K allele contributed to higher disease risk providing OR of 1.41 (P<0.0001). Accordingly, carriers homozygous for K/K showed significantly increased risk of developing T2D (OR=2.53, P<0.0001).
We considered age, gender, HbA1c, BMI, obesity, and hypertension as covariates that could influence association between the KCNJ11 E23K variant and disease. In homozygotes K/K, adjustment for these covariates resulted in reducing OR from 2.53 to 1.87, but association remained highly significant (P<0.0001).
The codon 1273 marker of ABCC8 also showed association with T2D ( Table 3 ). The carriage of the minor allele A was found to markedly strengthen the diabetes risk in both urban populations (OR=2.00, P<0.0001 in Moscow subjects and OR=2.13, P<0.0001 in Tyumen patients, respectively).
Compared to the homozygous G/G carriers, the carriage of homozygous A/A increased the diabetes risk approximately by 4-fold. Adjustment for confounding risk factors did not abolish but reduced the strength of association (in the pooled sample, OR=2.65 (A/A vs. G/G) and 2.11 (A/G vs. G/G), P<0.0001). Indeed, these data suggest that the KCNJ11 and ABCC8 variants represent independent risk factors contributing to genetic predisposition to T2D in a Russian population.
The KCNJ11 E23K and ABCC8 G/A R1273R variants, glucose tolerance, and β-cell function
Compared to the controls, the T2D patients have significantly elevated levels of both fasting and 2h plasma glucose and insulin. Previous studies have found that elevated levels of these products lead to impaired glucose tolerance and altered β-cell function (reviewed in [26] ). The value of HOMA-β was significantly reduced in affected patients (51.0±21.7 vs. 100.0±43.1, P<0.0001) thereby indicating disturbances in β-cell homeostasis ( Table 1) . Using a multiple logistic analysis, we tested whether markers rs5219 (KCNJ11) and rs1799859 (ABCC8) contribute to glucose intolerance and β-cell Table 6 . Association of the E23K KCNJ11 and ABCC8 R1273R G/A variants with patients' responses to anti-diabetic treatment with biguanides, sulfonylureas, thiazolydindiones, and meglitinides. Results are shown in percentages as mean ± S.D. Changes in serum levels of glucose, insulin, and HbA1c were measured before a 6-month treatment with anti-diabetic drugs. The variables were compared using the two-way ANOVA test. Abbreviations: HbA1c, glycated hemoglobin; HOMA-β, homeostasis model assessment of β-cell function, S.D., standard deviation.
Replication of association between polymorphisms of the pancreatic ATP-sensitive potassium channel and susceptibility to type 2 diabetes in two Russian urban populations dysfunction in a total population sample. The carriage of the E23K marker of KCNJ11 was highly correlated with 2 h serum insulin levels in diabetic patients ( Table 4) . Compared to other genotypes, carriers homozygous for the risk allele K had significantly elevated concentrations of 2 h serum insulin (P adjusted =0.044).
In diabetic and non-diabetic subjects, the ABCC8 G/A variant was correlated with higher 2h plasma insulin levels ( Table 5) . In control individuals, the homozygous A/A genotype also correlated with elevated 2 h glucose but reduced HOMA-β score (P adjusted = 0.041 and 0.019, respectively). These data suggest that association of the ABCC8 A/A variant with increased diabetes risk could arise from its relation to glucose intolerance and altered insulin secretion, as both result from dysfunction of insulinproducing β-cells.
Association of the KCNJ11 E23K and ABCC8 G/A R1273R variants with response to anti-diabetic therapy
We studied association between the KCNJ11 and ABCC8 gene variants and patients' responses to four major classes of anti-diabetic drugs (biguanides, thiazolydinediones, sulfonylureas, and meglitinides). Sulfonylureas and meglitinides affect the output of insulin through inhibiting KATP channels [27] . The follow-up data reflecting changes in blood glucose and insulin (both fasting and 2 h) and HbA1c levels after a 6-month anti-diabetic therapy were available for 217 (71% of 306) diabetic patients treated with biguanides, 178 (89% of 200) patients treated with sulfonylureas, 127 (86% of147) of subjects treated with thiazolydinediones, and 95 (85% of 111) of those who took meglitinides (Table 6) . In carriers of different KCNJ11 and ABCC8 genotypes, no significant changes in serum levels of glucose, insulin, and HbA1c were observed after a 6-week treatment with biguanides and thiazolydinediones (Table 6 ). After treatment with meglitinides, patients homozygous for K/K of KCNJ11 E23K showed significantly reduced changes in fasting glucose compared to E/K and E/E carriers (P=0.017). Compared to other genotypes, diabetic subjects who were homozygous A/A for the ABCC8 G/A R1273R variant had significantly reduced fasting glucose (P=0.035) when treated with sulfonylureas. After treatment with meglitinides, 2 h serum glucose declined significantly less in homozygotes A/A then that in carriers of G/G and A/G genotypes (P=0.045). Therefore, in Russian diabetic patients, the presence of the K/K variant of KCNJ11 E23K or the A/A variant of ABCC8 G/A R1273R is associated with a reduced response to both non-sulfonylurea and sulfonylurea blockers of the pancreatic KATP channel.
Discussion
Previously, using a small population sample (n=244), we found that the KCNJ11 E23K and ABCC8 R1273R G/A variants confer susceptibility to T2D (OR unadjusted=1.53 and 2.41 for the allele K of KCNJ11 and allele A of ABCC8, respectively) [18] . In this study, we extended this research to two independent cohorts comprising a total of 1185 individuals from geographically different areas (Moscow and Tyumen, Russia).
We showed a significant relationship between the presence of the was highly correlated with 2 h serum insulin levels .This may reflect the involvement of this genetic variant in altered post-OGTT insulin response. Our observations are consistent with results of several studies reporting correlation between the carriage of the K23 allele and reduced post-OGTT insulin release [10, 13] or lower C-peptide levels [28] in Caucasians. In overall, the E23K marker is associated with a reduction of estimates of glucose-induced serum insulin levels in Caucasians (KK vs. EE: OR=1.49; P=0.00022) [5] . Reduced secretion of insulin in KK carriers is in line with in vitro functional findings showing a link between the carriage of the allele K23 and reduced ATP sensitivity of the Kir6.2/SUR1 channel complex that results in the overactivity of the KATP and subsequent suppression of insulin secretion [8] .
The presence of the A allele of ABCC8 was significantly associated with increased 2 h insulin and, consequently, with reduced HOMA-β score in Russian non-diabetic patients ( Table 5 ). This finding in agreement with results of Goksel and coauthors [16] who reported an association of ABCC8 allele A with hyperinsulenemia both in the fasting state and following an oral glucose load in Mexican Americans. Elevated serum insulin observed in normoglycemic carriers of the ABCC codon 1273 A/A genotype in response to glucose stimulation could indicate the presence of dysregulated insulin secretion as a consequence of altered β-cell homeostasis and islet hyperactivity [29] .
Decreased insulin secretion in T2D may be preceded by stages of hypersecretion, and hyperinsulinism can be present in non-affected close relatives of T2D patients [30, 31] . A Finnish study showed increased insulin secretion in subjects with impaired glucose tolerance followed by a progressive decline in insulin levels as subjects become diabetic [32] . Initial hyperexcitability of islets under stress conditions such as a high-fat diet may therefore lead to further increase in excitability and cause a hypersecreting phenotype but then progress to an undersecretary diabetic phenotype and T2D due to the loss of compensatory β-cell function [7] .
We also observed association between the presence of the ABCC codon 1273 A/A and KCNJ11 K23K variants, which are related to higher diabetes risk, and lower response to therapy with sulfonylureas and meglitinides. This finding is consistent with results of several studies reported correlation between the carriage of the KCNJ11 K23 allele, lower efficiency of anti-diabetic therapy [33, 34] and higher risk of secondary failure to sulfonylureas in T2D patients [35] . The functional E23K polymorphism resides in the N-terminal portion of the Kir6.2 molecule, a region that has been shown to be crucial for the transduction of sulfonylurea binding into channel closure [36] . The synonymous substitution at codon 1273 of ABCC8 is rather non-functional since it does not cause an amino acid change. However, it could be in linkage disequilibrium (LD) with other polymorphism in ABCC8 that is functionally relevant. The codon 1273 polymorphism is located in the vicinity to a non-synonymous alanine-to-serine substitution at codon 1369 (A1369S, rs757110). Both polymorphisms are in strong linkage disequilibrium [37] . The codon 1369 polymorphic site lies near to the second nucleotidebinding fold domain of SUR1 and in turn may affect its binding affinity and influence the channel activity [38] .
Several reports showed association between the ABCC8 A1369S variant and responsiveness to gliclazide, a sulfonylurea [39, 40] . Data of the population studies were recently supported by results of the functional analysis of the recombinant KATP channel comprising either the predisposing K23/A1369 or protective E23/ S1369 variants. Compared to E23/S1369, the K23/ A1369 variant showed a 3-fold reduced sensitivity to ATP and displayed increased inhibition by gliclazide but not with glibenclamide or repaglinide, which bind to another site on the SUR1 molecule [41] . These data indicate that the common K23/A1369 variant of the KATP channel could represent an etiological functional variant for diabetes on chromosome 11p15.1 that contributes to the observed increased risk for T2D through reduced ATPinhibition. This may provide a suitable pharmacogenomic therapeutic target for T2D patients with type 2 diabetes who are homozygous for both risk alleles.
In conclusion, we have confirmed the previously reported association between the KCNJ11 E23K and ABCC8 codon 1273 G/A variants and susceptibility to T2D in a large cohort. According to our estimates, in Russian carriers of the homozygous KCNJ11 K/K variant, PAR is 4.3% and 3.0% after adjustment for covariate factors. These values are comparable with a summary PAR score (6.2%) reported in a meta-analysis [42] for clinical T2D in Caucasians carrying the KCNJ11 K/K genotype. For the ABCC R1273R A/A genotype, the crude PAR of 5.9% was reduced to 4.8% when adjusted for confounding risk factors. Our findings indicate that both common variants of ABCC8 and KCNJ11 had a modest impact on T2D risk in the Russian population.
